Glenmark Pharmaceuticals Ltd

Glenmark receives acceptance from U.S. FDA on its IND application for GRC 54276 to proceed with a Phase 1/2 first-in-human clinical study of the molecule for the treatmentof patients with advanced solid tumors and lymphomas